Daily Politics News Magazine
Covering Politics, Candidates & Issues from City Hall to Capitol Hill

Israeli company claims oral COVID-19 vaccine on its way

In addition, it is a yeast-based vaccine, making the time and cost of production much cheaper than its already approved competitors.

The advantages of an oral vaccine go beyond safety and efficacy, Kidron said. Oral medications tend to have fewer side effects.

In addition, the vaccine can be shipped at refrigerator temperatures and even stored at room temperature, “making it logistically easier to get it anywhere around the world,” Kidron said.
Finally, an oral vaccine would not require professional administration.
Oravax anticipates commencing a clinical study during the second quarter of 2021. It is applying for trials in multiple countries, including the United States, Israel, Europe and Mexico, Kidron said. It hopes to also target Africa, where such an oral vaccine could prove essential.
Kidron said he expects Phase I human trial data to be available within three months.
In February 2020, shortly after the start of the COVID-19 pandemic, another Israeli team began development on what they hoped would be an oral coronavirus vaccine. Scientists from the Galilee Research Institute’s biotechnology group said they were primed to develop their vaccine within a few months.
They had been developing a vaccine against avian coronavirus, which had been proven effective in preclinical trials, and they believed it would translate to a human vaccine. Despite a commitment by the Science and Technology Ministry to fast-track approval of the vaccine and a $12 million investment by OurCrowd, the vaccine has yet to come to market.

The Post contacted the institute’s researchers and representatives several times in recent months for a status update, but none was provided.

Read More: Israeli company claims oral COVID-19 vaccine on its way

Notify of
Inline Feedbacks
View all comments

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.